Professor Kim conducted a comparative analysis of the effects of 'RCI001' and '1% prednisolone (PDE steroid),' currently the most potent topical 抗炎 agent in use, in an 动物模型 of 眼部 chemical burn.
The research results revealed that 'RCI001' was superior in 疗效 and had fewer 副作用 compared to the existing steroid drug.
Specifically, 'RCI001' outperformed the steroid in 角膜上皮 defect and transparency recovery, infiltration of 炎症 cells within 角膜 tissue, '炎症细胞因子' that cause excessive 炎症 on the 眼表面, and '氧化应激 markers' indicating cell damage caused by 活性氧 in the body.
In contrast, 眼内压升高 — a representative 副作用 commonly found with steroid drugs — was not observed with 'RCI001.'
Professor Kim's research was published under the title 'Comparison of therapeutic effects between topical 8‑oxo‑2′‑deoxyguanosine and prednisolone in a rabbit model of acute 眼部 chemical injury,' drawing significant attention from the academic community for providing a scientific basis for the potential of RCI001 as a next-generation 眼科 treatment.